An Open-label Phase 2 Study of Carfilzomib Plus Dexamethasone To Assess Tolerability and Adherence in Subjects With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers
Phase of Trial: Phase II
Latest Information Update: 19 Jan 2019
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Amgen
- 07 Dec 2018 Planned End Date changed from 21 Dec 2020 to 15 Jan 2024.
- 07 Dec 2018 Planned primary completion date changed from 21 Dec 2020 to 15 Jan 2024.
- 24 Oct 2018 Planned End Date changed from 28 Mar 2021 to 21 Dec 2020.